CEACAM5 and neoplasm: The pretargeting technique uses a bispecific monoclonal antibody bs-mAb (a multivalent, recombinant anti-CEA, carcinoembryonic antigen/anti-HSG histamine-succinyl-glycine fusion protein) with the affinity for a tumor and a small hapten peptide.